每周一次司美格鲁肽2·4 mg与安慰剂在肥胖合并糖尿病前期人群中的疗效与安全性(STEP 10):一项随机、双盲、安慰剂对照、多中心3期试验
STEP 10是一项在加拿大、丹麦、芬兰、西班牙和英国30个中心开展的随机、双盲、安慰剂对照3期试验,纳入BMI≥30 kg/m²且符合英国国家卫生与临床优化研究所糖尿病前期标准的成人。受试者按2:1随机接受每周皮下司美格鲁肽2·4 mg或安慰剂并辅以饮食和体力活动咨询52周,随后停药28周。第52周时,司美格鲁肽2·4 mg较安慰剂显著降低体重并提高血糖正常恢复比例,安全性与既往研究及GLP-1受体激动剂类药物一致。
要点
- 第52周体重降幅:司美格鲁肽2·4 mg组-13·9% vs 安慰剂组-2·7%,估计治疗差异-11·2%(95% CI -13·0至-9·4;p<0·0001)。
- 第52周恢复血糖正常比例:司美格鲁肽2·4 mg组103/127(81%)vs 安慰剂组9/64(14%),OR 19·8(95% CI 8·7至45·2;p<0·0001)。
- 严重不良事件:司美格鲁肽2·4 mg组12例(9%)vs 安慰剂组6例(9%);导致停药的不良事件分别为8例(6%)vs 1例(1%)。
核心结论
- 在肥胖合并糖尿病前期受试者中,司美格鲁肽2·4 mg较安慰剂显著降低体重并提高恢复血糖正常的比例。
- 安全性和耐受性与既往研究及GLP-1受体激动剂类药物一致。
- 这些发现支持司美格鲁肽2·4 mg作为肥胖合并糖尿病前期个体实现血糖正常恢复的潜在治疗选择。
研究设计与样本
- STEP 10为随机、双盲、平行组、3期试验,在加拿大、丹麦、芬兰、西班牙和英国的30个试验中心开展。
- 纳入18岁及以上、BMI≥30 kg/m²且符合英国国家卫生与临床优化研究所糖尿病前期标准的受试者。
- 受试者按2:1随机分配至每周皮下司美格鲁肽2·4 mg或安慰剂,同时接受饮食和体力活动咨询52周,随后停药28周。
- 主要终点为第52周体重百分比变化和恢复血糖正常(HbA1c<6·0%[<42 mmol/mol]且FPG<5·5 mmol/L)的受试者比例,按意向治疗分析全部随机分配受试者。
- 2021年9月16日至12月29日期间,138例随机分配至司美格鲁肽2·4 mg组,69例至安慰剂组;147例(71%)为女性,60例(29%)为男性;183例(88%)为白人。
主要发现
- 基线平均年龄53岁(SD 11),体重111·6 kg(22·2),BMI 40·1 kg/m²(6·9),腰围120·1 cm(14·7),HbA1c 5·9%(0·3;41·3 mmol/mol[3·0]),FPG 5·9 mmol/L(0·6)。
- 第52周体重降幅:司美格鲁肽2·4 mg组-13·9%(SD 0·7)vs 安慰剂组-2·7%(0·6);估计治疗差异-11·2%(95% CI -13·0至-9·4);p<0·0001。
- 第52周恢复血糖正常比例:司美格鲁肽2·4 mg组103/127(81%)vs 安慰剂组9/64(14%);OR 19·8(95% CI 8·7至45·2);p<0·0001。
- 严重不良事件:司美格鲁肽2·4 mg组12例(9%)vs 安慰剂组6例(9%)。
- 导致治疗中止的不良事件:司美格鲁肽2·4 mg组8例(6%)vs 安慰剂组1例(1%);未报告新的安全性信号。
关键数值与推荐
- 糖尿病前期定义依据英国国家卫生与临床优化研究所标准:筛查时HbA1c 6·0-6·4%(42-47 mmol/mol)或FPG 5·5-6·9 mmol/L中至少满足一项。
- 恢复血糖正常定义为HbA1c<6·0%(<42 mmol/mol)且FPG<5·5 mmol/L。
临床怎么用
- 作者认为,这些发现支持司美格鲁肽2·4 mg作为肥胖合并糖尿病前期个体实现血糖正常恢复的潜在治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are currently limited data regarding the effect of semaglutide 2·4 mg in individuals with obesity and prediabetes in clinical trials. We aimed to assess the efficacy and safety of semaglutide 2·4 mg for weight management and glycaemic control in participants with obesity and prediabetes. METHODS: STEP 10 was a randomised, double-blind, parallel-group, phase 3 trial done across 30 trial sites in Canada, Denmark, Finland, Spain, and the UK and included participants aged 18 years or older with a BMI of 30 kg/m2 or higher and prediabetes according to UK National Institute for Health and Care Excellence criteria (defined as having at least one of the following at screening: HbA1c of 6·0-6·4% [42-47 mmol/mol] or fasting plasma glucose [FPG] of 5·5-6·9 mmol/L). Participants were randomly assigned (2:1) to once-weekly subcutaneous semaglutide 2·4 mg or placebo with diet and physical activity counselling for 52 weeks, followed by a 28-week off-treatment period. Primary endpoints were percentage change in bodyweight and proportion of participants reverting to normoglycaemia (HbA1c <6·0% [<42 mmol/mol] and FPG <5·5 mmol/L) at week 52 (assessed in all randomly assigned participants by intention to treat). Selective safety data were collected for participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT05040971, and is complete. FINDINGS: Between Sept 16 and Dec 29, 2021, 138 participants were randomly assigned to semaglutide 2·4 mg and 69 to placebo. 147 (71%) were female and 60 (29%) were male; 183 (88%) were White. All randomly assigned participants received at least one dose of study drug. Baseline mean age was 53 years (SD 11), bodyweight 111·6 kg (22·2), BMI 40·1 kg/m2 (6·9), waist circumference 120·1 cm (14·7), HbA1c 5·9% (0·3; 41·3 mmol/mol [3·0]), and FPG 5·9 mmol/L (0·6). There was a significantly greater reduction in bodyweight with semaglutide 2·4 mg than with placebo at week 52 (-13·9% [SD 0·7] vs -2·7% [0·6]; estimated treatment difference -11·2% [95% CI -13·0 to -9·4]; p<0·0001). Greater proportions of participants reverted to normoglycaemia at week 52 with semaglutide 2·4 mg than with placebo (103 [81%] of 127 vs nine [14%] of 64; odds ratio 19·8 [95% CI 8·7 to 45·2]; p<0·0001). Serious adverse events occurred in 12 (9%) participants receiving semaglutide 2·4 mg versus six (9%) receiving placebo. Adverse events leading to treatment discontinuation occurred in eight (6%) participants in the semaglutide 2·4 mg group versus one (1%) participant in the placebo group. No new safety signals were reported. INTERPRETATION: Semaglutide 2·4 mg provided superior reduction in bodyweight and reversion to normoglycaemia versus placebo in participants with obesity and prediabetes. The safety and tolerability profile was consistent with previous studies and with the GLP-1 receptor agonist class. These findings support the potential use of semaglutide 2·4 mg as a treatment option for individuals with obesity and prediabetes to achieve reversion to normoglycaemia. FUNDING: Novo Nordisk. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.
引用
- McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024. PMID: 39089293. doi:10.1016/S2213-8587(24)00182-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。